112 related articles for article (PubMed ID: 23122594)
1. Enhanced anti-angiogenesis and anti-tumor activity of endostatin by chemical modification with polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Liu C; Cao J; Mu G; Wang F
Biomed Pharmacother; 2012 Dec; 66(8):648-54. PubMed ID: 23122594
[TBL] [Abstract][Full Text] [Related]
2. Characterization and secondary structure analysis of endostatin covalently modified by polyethylene glycol and low molecular weight heparin.
Tan H; Yang S; Feng Y; Liu C; Cao J; Mu G; Wang F
J Biochem; 2008 Aug; 144(2):207-13. PubMed ID: 18463113
[TBL] [Abstract][Full Text] [Related]
3. Endostatin derivative angiogenesis inhibitors.
Zheng MJ
Chin Med J (Engl); 2009 Aug; 122(16):1947-51. PubMed ID: 19781376
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of vascular endothelial growth factor and up-regulation of pigment epithelium derived factor make low molecular weight heparin-endostatin and polyethylene glycol-endostatin potential candidates for anti-angiogenesis drug.
Tan H; Mu G; Zhu W; Liu J; Wang F
Biol Pharm Bull; 2011; 34(4):545-50. PubMed ID: 21467643
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.
Bai Y; Zhao M; Zhang C; Li S; Qi Y; Wang B; Huang L; Li X
PLoS One; 2014; 9(11):e112448. PubMed ID: 25380141
[TBL] [Abstract][Full Text] [Related]
6. Preparation, characterization and anti-angiogenesis activity of endostatin covalently modified by polysulfated heparin.
Ning TH; Chao CJ; Ying MG; Min X; Shan WF
Pharmazie; 2012 Jul; 67(7):622-7. PubMed ID: 22888520
[TBL] [Abstract][Full Text] [Related]
7. Higher Anti-angiogenesis Activity, Better Cellular Uptake and Longer Half-life of a Novel Glyco-modified Endostatin by Polysulfated Heparin.
Sun F; Shaikh AS; Wang J; Gao H; Yang Z; Wang Z; Li Y; Wang F; Tan H
Curr Pharm Biotechnol; 2018; 19(12):996-1004. PubMed ID: 30761959
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo.
Schuch G; Oliveira-Ferrer L; Loges S; Laack E; Bokemeyer C; Hossfeld DK; Fiedler W; Ergun S
Leukemia; 2005 Aug; 19(8):1312-7. PubMed ID: 15931265
[TBL] [Abstract][Full Text] [Related]
9. Augmented anti-angiogenesis activity of polysulfated heparin-endostatin and polyethylene glycol-endostatin in alkali burn-induced corneal ulcers in rabbits.
Li ZN; Yuan ZF; Mu GY; Hu M; Cao LJ; Zhang YL; Ge MX
Exp Ther Med; 2015 Sep; 10(3):889-894. PubMed ID: 26622410
[TBL] [Abstract][Full Text] [Related]
10. Site-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa.
Zhu B; Xu HM; Zhao L; Huang X; Zhang F
J Biochem; 2010 Sep; 148(3):341-7. PubMed ID: 20587645
[TBL] [Abstract][Full Text] [Related]
11. [Inhibition of corneal neovascularization by liposomes mediated plasmid encoding human endostatin].
Niu XG; Wang W; Shi WY; Xie LX
Zhonghua Yan Ke Za Zhi; 2005 Mar; 41(3):260-4. PubMed ID: 15840371
[TBL] [Abstract][Full Text] [Related]
12. Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate.
Lee DY; Kim SK; Kim YS; Son DH; Nam JH; Kim IS; Park RW; Kim SY; Byun Y
J Control Release; 2007 Apr; 118(3):310-7. PubMed ID: 17291620
[TBL] [Abstract][Full Text] [Related]
13. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin.
Morbidelli L; Donnini S; Chillemi F; Giachetti A; Ziche M
Clin Cancer Res; 2003 Nov; 9(14):5358-69. PubMed ID: 14614021
[TBL] [Abstract][Full Text] [Related]
14. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y
J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701
[TBL] [Abstract][Full Text] [Related]
15. N-/C-terminal deleted mutant of human endostatin efficiently acts as an anti-angiogenic and anti-tumorigenic agent.
Cho H; Kim WJ; Lee YM; Kim YM; Kwon YG; Park YS; Choi EY; Kim KW
Oncol Rep; 2004 Jan; 11(1):191-5. PubMed ID: 14654925
[TBL] [Abstract][Full Text] [Related]
16. Endostatin specifically targets both tumor blood vessels and lymphatic vessels.
Zhuo W; Chen Y; Song X; Luo Y
Front Med; 2011 Dec; 5(4):336-40. PubMed ID: 22198745
[TBL] [Abstract][Full Text] [Related]
17. Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice.
Schaffhauser B; Veikkola T; Strittmatter K; Antoniadis H; Alitalo K; Christofori G
J Leukoc Biol; 2006 Oct; 80(4):669-76. PubMed ID: 16793908
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer.
Wang N; Gao Q; Tang J; Jiang Y; Yang L; Shi X; Chen Y; Zhang Y; Fu S; Lin S
Drug Deliv; 2021 Dec; 28(1):183-194. PubMed ID: 33427520
[TBL] [Abstract][Full Text] [Related]
19. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
20. The effect of intracellular protein delivery on the anti-tumor activity of recombinant human endostatin.
Lim J; Duong T; Lee G; Seong BL; El-Rifai W; Ruley HE; Jo D
Biomaterials; 2013 Aug; 34(26):6261-71. PubMed ID: 23714245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
